Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026)
Immix Biopharma (IMMX) posted Income from Continuing Operations of 10086687.0 for Q1 2026, down 317.98% sequentially from 2413182.0 in Q4 2025, and down 122.05% YoY from 45744448.93 in Q1 2025.
Powered by 
Analysis
Immix Biopharma (IMMX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Income from Continuing Operations for 6 years, with the latest figure at 10086687.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 122.05% year-over-year to 10086687.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26708124.0 (down 3259.47% YoY) and the FY2025 annual result came in at 21163965.0, down 1236.49% from the prior year.
- Income from Continuing Operations slipped to 10086687.0 in Q1 2026 per IMMX's latest filing, from 2413182.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 15302762.0 in Q4 2024 and troughed at 10086687.0 in Q1 2026.
- A 5-year average of 2975154.88 and a median of 3598212.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 649.04% in 2022, then jumped 1965.89% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2053268.0 in 2022, then surged by 60.06% to 820134.0 in 2023, then surged by 1965.89% to 15302762.0 in 2024, then slumped by 115.77% to 2413182.0 in 2025, then sank by 317.98% to 10086687.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 10086687.0, 2413182.0, and 7585692.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immix Biopharma | 889.29 Mn | 889.29 Mn | - | -11.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.56 Mn |
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -4.41 Mn |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -820,134.00 |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -2.50 Mn |
| Dec 31, 2022 | -2.05 Mn |
| Sep 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -17.63 Mn |
| Sep 30, 2021 | -403,265.00 |